Stakeholders' expectations of precision medicine: A qualitative study to identify areas of (mis)alignment

Author:

Knott Tanya12,Creeden James23,Horbach Benjamin45,Rauch‐Zumbrägel Maximiliane6ORCID,Vat Lidewij6,Harnik Helena6ORCID,Maravic Zorana57

Affiliation:

1. Sarah Jennifer Knott Foundation Dublin Ireland

2. From Testing to Targeted Treatments (FT3) Board Member, The Synergist Brussels Belgium

3. Creeden Consulting Basel Switzerland

4. F. Hoffmann‐La Roche Ltd. Basel Switzerland

5. From Testing to Targeted Treatments (FT3) Member, The Synergist Brussels Belgium

6. From Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium

7. Digestive Cancers Europe Brussels Belgium

Abstract

AbstractBackground and AimsTo sustainably address challenges in implementing precision medicine (PM), coordinated efforts of different stakeholders are required. Understanding their expectations represents a first key step toward aligning on future actions and strategies. Here, we aimed to explore the expectations of different stakeholders from themselves and each other regarding PM.MethodsThis collaborative qualitative study was initiated by the global multistakeholder consortium From Testing to Targeted Treatments (FT3). Structured interviews were conducted with participants from five stakeholder groups: patients/patient advocates, healthcare providers (HCPs), researchers, policymakers/regulators/payers and industry representatives. A broad reach across geography, roles, experiences, and disease areas was sought. Results were analyzed by grounded theory methodology.ResultsAll stakeholders stated that optimal implementation of PM can only be achieved through collaboration; industry representatives were the biggest promoters of collaboration. Stakeholders agreed that PM should be implemented focusing on the patient's best interest; HCPs were seen as important gatekeepers for PM by interacting directly with patients, and policymakers/payers were perceived as the most important drivers of access to PM. Areas of misalignment included the role of industry in clinical trial design and in access to PM (perceived as important by patients, HCPs and policymakers but not by industry representatives), and the stakeholders responsible for elaborating guidelines on PM use (patients indicated policymakers, while researchers indicated themselves). Priorities for optimal PM implementation and suggested actions included the need for enhancing high‐level policy focus, improving genomic literacy, optimizing the health technology assessment for PM, advocating for equitable access, promoting collaboration between industry and other stakeholder groups and development of reliable research standards.ConclusionStakeholder expectations revealed in this study suggested that no stakeholder group can drive change on its own; a global, multistakeholder collaborative approach that brings together current programs and best practices to support universal access to PM is needed.

Publisher

Wiley

Subject

General Medicine

Reference36 articles.

1. Milestones in Personalized Medicine: From the Ancient Time to Nowadays—the Provocation of COVID-19

2. Precision Medicine

3. Precision medicine. European Federation of Pharmaceutical Industries and Associations. Accessed July 152022.https://www.efpia.eu/about-medicines/development-of-medicines/precision-medicine/

4. The Distinctive Nature of HER2-Positive Breast Cancers

5. Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3